Market News

Golar LNG Limited (GLNG) EPS Estimated At $-0.22; Last Week PDL BioPharma, Inc. (PDLI) Analysts

PDL BioPharma, Inc. (NASDAQ:PDLI) Logo

Among 4 analysts covering PDL BioPharma (NASDAQ:PDLI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. PDL BioPharma had 9 analyst reports since October 16, 2015 according to SRatingsIntel. The stock has “Sector Perform” rating by RBC Capital Markets on Thursday, November 5. Cowen & Co maintained PDL BioPharma, Inc. (NASDAQ:PDLI) rating on Friday, August 4. Cowen & Co has “Hold” rating and $300 target. The firm earned “Sector Perform” rating on Tuesday, February 23 by RBC Capital Markets. Cowen & Co maintained it with “Hold” rating and $3.0 target in Thursday, October 26 report. The company was maintained on Tuesday, February 2 by RBC Capital Markets. Piper Jaffray maintained the stock with “Buy” rating in Friday, November 3 report. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, October 16. The rating was maintained by PiperJaffray with “Overweight” on Thursday, December 22. See PDL BioPharma, Inc. (NASDAQ:PDLI) latest ratings:

Analysts expect Golar LNG Limited (NASDAQ:GLNG) to report $-0.22 EPS on May, 30.They anticipate $0.19 EPS change or 46.34% from last quarter’s $-0.41 EPS. After having $-0.11 EPS previously, Golar LNG Limited’s analysts see 100.00% EPS growth. The stock increased 1.13% or $0.38 during the last trading session, reaching $33.98. About 806,807 shares traded. Golar LNG Limited (NASDAQ:GLNG) has risen 1.30% since May 18, 2017 and is uptrending. It has underperformed by 10.25% the S&P500.

Another recent and important Golar LNG Limited (NASDAQ:GLNG) news was published by Seekingalpha.com which published an article titled: “Golar LNG: Playing The Turnaround” on April 25, 2018.

Golar LNG Limited, a midstream liquefied natural gas company, engages in the transportation, regasification, liquefaction, and trading of LNG. The company has market cap of $3.44 billion. The firm operates through Vessel Operations, LNG Trading, FLNG, and Power divisions. It currently has negative earnings. It is involved in the acquisition, ownership, operation, and chartering of LNG carriers and floating storage regasification units (FSRUs); and the development of LNG projects.

Among 12 analysts covering Golar LNG Limited (NASDAQ:GLNG), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. Golar LNG Limited had 30 analyst reports since August 18, 2015 according to SRatingsIntel. The company was upgraded on Friday, August 28 by Stifel Nicolaus. The company was upgraded on Monday, October 3 by ABN Amro. Stifel Nicolaus maintained Golar LNG Limited (NASDAQ:GLNG) rating on Thursday, April 19. Stifel Nicolaus has “Buy” rating and $4200 target. Cowen & Co maintained the shares of GLNG in report on Thursday, October 20 with “Outperform” rating. The stock of Golar LNG Limited (NASDAQ:GLNG) earned “Buy” rating by Jefferies on Friday, January 26. Credit Suisse upgraded the stock to “Outperform” rating in Monday, May 9 report. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, August 21. Credit Suisse initiated the stock with “Neutral” rating in Friday, September 18 report. Cowen & Co maintained the stock with “Buy” rating in Thursday, November 30 report. The rating was maintained by Cowen & Co on Tuesday, December 12 with “Buy”.

More recent PDL BioPharma, Inc. (NASDAQ:PDLI) news were published by: Seekingalpha.com which released: “PDL Biopharma: Activist Investor, Enter Stage Right” on April 27, 2018. Also Seekingalpha.com published the news titled: “PDL BioPharma’s (PDLI) CEO John McLaughlin on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018. Fool.com‘s news article titled: “3 Top Stocks Under $5” with publication date: May 17, 2018 was also an interesting one.

Investors sentiment decreased to 1.13 in Q4 2017. Its down 0.37, from 1.5 in 2017Q3. It fall, as 18 investors sold PDL BioPharma, Inc. shares while 52 reduced holdings. 26 funds opened positions while 53 raised stakes. 134.59 million shares or 2.55% more from 131.24 million shares in 2017Q3 were reported. Jpmorgan Chase Com holds 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 581,580 shares. Mackenzie Fincl accumulated 4.85 million shares. Bnp Paribas Arbitrage Sa reported 69,897 shares stake. Ameriprise Fin Inc owns 379,922 shares. California State Teachers Retirement System invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Whittier Tru Of Nevada Inc reported 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Proshare Advsr Ltd Liability Corp reported 106,779 shares or 0% of all its holdings. Fmr Limited Liability Corp holds 151,780 shares. Parallax Volatility Advisers L P invested in 0% or 24,444 shares. Connor Clark Lunn Investment Mngmt Limited owns 3.65M shares for 0.06% of their portfolio. Stratos Wealth Prtnrs Limited owns 2,300 shares. 267,641 are owned by Aperio Lc. Bridgeway has 0.03% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 851,000 shares. State Street holds 0% or 8.57 million shares in its portfolio. Wealthtrust Axiom Limited Liability Company reported 33,000 shares stake.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *